Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Worldwide prevalence and burden of gastroparesis-like symptoms as defined by the United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis.

United European gastroenterology journal·2022

Same author

Editorial: refractory reflux sensitivity-A place for baclofen? Authors' reply.

Alimentary pharmacology & therapeutics·2022

Same author

Exploring the pathophysiology of LARS after low anterior resection for rectal cancer with high-resolution colon manometry.

Neurogastroenterology and motility·2022

Same author

Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.

United European gastroenterology journal·2022

Same author

Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms.

Alimentary pharmacology & therapeutics·2022

Same author

Zhizhu Kuanzhong Capsule in treating patients with functional dyspepsia postprandial distress syndrome: study protocol for a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial.

Trials·2022

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

Emerging drugs for functional dyspepsia.

Jan Tack¹, Pieter Janssen

¹University of Leuven, TARGID, Department of Pathophysiology, Herestraat 49, 0&N 1, bus 701, B-3000 Leuven, Belgium. jan.tack@med.kuleuven.be

Expert Opinion on Emerging Drugs

|March 19, 2011

Summary

New drug development for functional dyspepsia (FD) shows promise, particularly acotiamide, a fundic relaxant. While gastroprokinetics are explored, evidence for psychotropics in FD remains limited.

Area of Science:

Gastroenterology
Pharmacology
Drug Development

Background:

Functional dyspepsia (FD) is a common condition impacting quality of life and incurring significant healthcare costs.
Currently, no established effective treatments exist for FD.
Recent advancements focus on novel drug development to address this unmet medical need.

Purpose of the Study:

To review recent progress in drug development for functional dyspepsia (FD).
To evaluate the therapeutic potential of novel agents, including gastroprokinetics and fundic relaxants.
To assess the efficacy of psychotropic medications in refractory FD cases.

Main Methods:

Literature review of recent drug development for FD.
Summary of studied gastroprokinetic agents targeting 5-HT(4), motilin, and ghrelin receptors.

More Related Videos

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Published on: July 26, 2024

Related Experiment Videos

Last Updated: Jun 3, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Published on: July 26, 2024

Analysis of novel fundic relaxant drugs, including 5-HT(1A) receptor agonists and acotiamide.

Evaluation of psychotropic agents like venlafaxine and flupenthixol/melitracen.

Main Results:

Several new prokinetic drugs are in early development stages.
Acotiamide, a muscarinic antagonist and cholinesterase inhibitor, shows promising efficacy, especially for postprandial distress syndrome.
Psychotropic agents like venlafaxine lacked confirmed efficacy in large studies, while flupenthixol/melitracen showed potential in a small trial.

Conclusions:

Acotiamide presents a promising efficacy profile for functional dyspepsia treatment.
Further research is needed for novel prokinetic drugs.
Convincing evidence for the efficacy of psychotropics in FD is currently lacking.